Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14412 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Pongthep Vittayawacharin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of Californ…. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Data on bone marrow (BM) findings in secondary hemophagocytic lymphohistiocytosis (sHLH) and their association with overall survival (OS) are limited.
Objectives
This study aimed to develop a prognostic model incorporating BM findings and clinico‐laboratory factors affecting OS.
Methods
We retrospectively evaluated 50 adults with sHLH and developed a clinicopathological prognostic model based on survival‐associated factors.
Results
Most patients demonstrated normocellular BM (46.3%) and mild hemophagocytic activity (44.2%). Factors associated with survival in multivariable analyses (MVA) were age above 70 years (hazard ratio [HR] 3.89, p = 0.016), infection‐related (HR 4.62, p = 0.006), hemoglobin < 7 g/dL (HR 5.21, p < 0.001), and hypocellular marrow (HR 3.07, p = 0.04). A clinicopathological HLH risk model assigned 1 point to each MVA‐identified survival factor, categorizing patients into low‐ (score 0–1), intermediate‐ (score 2–3), and high‐risk (score 4) groups. The 6‐month OS from bootstrapping internal validation among the low‐, intermediate‐, and high‐risk groups were 84.2%, 55.6% ( p < 0.001) and 7.7% ( p < 0.001), respectively. The area under the receiver operating characteristic curve (AuROC) was 0.87.
Conclusions
This model stratified sHLH patients into three risk groups with distinct survival outcomes, potentially guiding future therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.
- Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Pharmacy, University of California Irvine Health, Orange, California, USA.
- Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, California, USA.
- Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Irvine, California, USA.
- Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, USA.
ORCID-Profile: Pongthep Vittayawacharin, Benjamin J Lee
Förderung
- NCI NIH HHS
Zitieren
APA
Vittayawacharin, P., Lee, B. J., E'leimat, G., Cao, Y., Reid, J., Gamayo, A., Rezk, S., Brem, E. A., Lee, L. X., Kongtim, P., & Ciurea, S. O. (2025). Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis. European Journal of Haematology. https://doi.org/10.1111/ejh.14412
Vancouver
Vittayawacharin P, Lee BJ, E'leimat G, Cao Y, Reid J, Gamayo A, et al. Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis. European Journal of Haematology. 2025. doi:10.1111/ejh.14412
BibTeX
@article{Vittayawacharin2025,
author = {Vittayawacharin, Pongthep and Lee, Benjamin J and E'leimat, Ghayda' and Cao, Yen and Reid, Jack and Gamayo, Ashley and Rezk, Sherif and Brem, Elizabeth A and Lee, Lisa X and Kongtim, Piyanuch and Ciurea, Stefan O},
title = {Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14412}
}
EUVIMED